Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Autolus Therapeutics plcAUTL · Entity 1933 | Director | June 29, 2026 | July 01, 2026 |
| IMMUNOMEDICS INCIMMU · Entity 145732 | CHIEF MEDICAL OFFICER | March 14, 2019 | March 18, 2019 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | EVP, Global Head of R&D & CMO | August 27, 2026 | August 31, 2026 |
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Director | July 09, 2026 | July 13, 2026 |
| iTeos Therapeutics, Inc.ITOS · Entity 75965 | Director | June 11, 2024 | June 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Autolus Therapeutics plc
Report date June 29, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 31,667 |
Reported balance
After 2026-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-29 · Grant · Acquired 31,667 · Balance 31,667 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share. F2: The RSUs vest in one installment on June 29, 2027. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2036-06-29 | Direct | 47,500 |
Reported balance
After 2026-06-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-29 · Grant · Acquired 47,500 · Balance 47,500 F3: Share options vest in twelve equal monthly installments commencing on July 29, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share.
F2: The RSUs vest in one installment on June 29, 2027.
F3: Share options vest in twelve equal monthly installments commencing on July 29, 2026.
IMMUNOMEDICS INC
Report date March 14, 2019 · Filed March 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2026-03-14 | Direct | 51,230 |
Reported balance
After 2019-03-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-14 · Grant · Acquired 51,230 · Balance 51,230 F1: The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan (the "Plan"). The stock options vest 25% on the first anniversary of the date of grant, and in 6.25% in equal quarterly installments thereafter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2026-03-14 | Direct | 25,660 |
Reported balance
After 2019-03-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-14 · Grant · Acquired 25,660 · Balance 25,660 F2: The reporting person was granted stock options pursuant to the Plan. The stock options vest (i) 50% upon the Issuer's receipt of approval from the U.S. Food and Drug Administration for the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act, and (ii) 50% on the second anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan (the "Plan"). The stock options vest 25% on the first anniversary of the date of grant, and in 6.25% in equal quarterly installments thereafter.
F2: The reporting person was granted stock options pursuant to the Plan. The stock options vest (i) 50% upon the Issuer's receipt of approval from the U.S. Food and Drug Administration for the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act, and (ii) 50% on the second anniversary of the date of grant.
Jazz Pharmaceuticals plc
Report date August 27, 2026 · Filed August 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 65,686 |
Ending reported balance
After 2026-08-27 transaction · row 10
10 source rows · reconciled sequenceRow 1 · 2026-08-27 · Exercise / conversion · Acquired 26,116 · Balance 111,223 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Row 2 · 2026-08-27 · Exercise / conversion · Acquired 884 · Balance 112,107 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Row 3 · 2026-08-27 · Exercise / conversion · Acquired 27,584 · Balance 139,691 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Row 4 · 2026-08-27 · Exercise / conversion · Acquired 2,916 · Balance 142,607 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Row 5 · 2026-08-27 · Sale · Disposed 18,187 · Balance 124,420 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $247.29 to $248.24. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Row 6 · 2026-08-27 · Sale · Disposed 11,423 · Balance 112,997 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $248.29 to $249.24. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Row 7 · 2026-08-27 · Sale · Disposed 18,113 · Balance 94,884 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $249.33 to $250.325 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Row 8 · 2026-08-27 · Sale · Disposed 19,639 · Balance 75,245 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F5: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $250.33 to $251.29. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Row 9 · 2026-08-27 · Sale · Disposed 9,259 · Balance 65,986 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F6: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $251.37 to $252.31. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Row 10 · 2026-08-27 · Sale · Disposed 300 · Balance 65,686 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $113.10 · Expires 2030-02-26 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-08-27 · Exercise / conversion · Disposed 884 · Balance 0 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F7: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $137.12 · Expires 2029-08-07 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-08-27 · Exercise / conversion · Disposed 2,916 · Balance 0 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F8: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of May 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $113.10 · Expires 2030-02-26 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-08-27 · Exercise / conversion · Disposed 26,116 · Balance 0 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F7: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $137.12 · Expires 2029-08-07 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-08-27 · Exercise / conversion · Disposed 27,584 · Balance 0 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F8: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of May 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $247.29 to $248.24. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $248.29 to $249.24. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $249.33 to $250.325 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F5: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $250.33 to $251.29. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F6: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $251.37 to $252.31. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F7: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.
F8: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of May 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter.
PLIANT THERAPEUTICS, INC.
Report date July 09, 2026 · Filed July 13, 2026
This filing explicitly reported no securities owned.
iTeos Therapeutics, Inc.
Report date June 11, 2024 · Filed June 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.32 · Expires 2034-06-11 | Direct | 24,200 |
Reported balance
After 2024-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-11 · Grant · Acquired 24,200 · Balance 24,200 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Jounce Therapeutics, Inc.
Report date May 03, 2023 · Filed May 04, 2023
Section 16 reporting ended · disclosed 2023-05-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.19 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-03 · Disposition to issuer · Disposed 31,400 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of March 26, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 3, 2023 (the "Effective Time"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.58 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-05-03 · Disposition to issuer · Disposed 7,850 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.27 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-05-03 · Disposition to issuer · Disposed 15,700 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.80 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-05-03 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of March 26, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 3, 2023 (the "Effective Time").
F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 27, 2026 Filed Aug 31, 2026 22:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 27,584 | $0.00 Strike: $137.12 | $0.00 |
DisclosureSEC source: 0001737329-26-000016 · edgardoc.xml · derivative · entry 14 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 27,584 shares Expires 2029-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F8 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of May 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 22:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 26,116 | $0.00 Strike: $113.10 | $0.00 |
DisclosureSEC source: 0001737329-26-000016 · edgardoc.xml · derivative · entry 13 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 26,116 shares Expires 2030-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F7 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 22:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,916 | $0.00 Strike: $137.12 | $0.00 |
DisclosureSEC source: 0001737329-26-000016 · edgardoc.xml · derivative · entry 12 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,916 shares Expires 2029-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F8 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of May 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 22:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 884 | $0.00 Strike: $113.10 | $0.00 |
DisclosureSEC source: 0001737329-26-000016 · edgardoc.xml · derivative · entry 11 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 884 shares Expires 2030-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F7 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 22:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 300 | $252.76 | $75,828.00 |
DisclosureSEC source: 0001737329-26-000016 · edgardoc.xml · nonDerivative · entry 10 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,686 F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 22:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 9,259 | $251.95 | $2,332,804.12 |
DisclosureSEC source: 0001737329-26-000016 · edgardoc.xml · nonDerivative · entry 9 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,986 F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F6 · price: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $251.37 to $252.31. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 22:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 19,639 | $250.60 | $4,921,596.24 |
DisclosureSEC source: 0001737329-26-000016 · edgardoc.xml · nonDerivative · entry 8 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,245 F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F5 · price: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $250.33 to $251.29. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 22:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 18,113 | $250.02 | $4,528,572.41 |
DisclosureSEC source: 0001737329-26-000016 · edgardoc.xml · nonDerivative · entry 7 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,884 F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $249.33 to $250.325 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 22:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 11,423 | $248.67 | $2,840,516.29 |
DisclosureSEC source: 0001737329-26-000016 · edgardoc.xml · nonDerivative · entry 6 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,997 F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $248.29 to $249.24. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 22:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 18,187 | $247.86 | $4,507,780.72 |
DisclosureSEC source: 0001737329-26-000016 · edgardoc.xml · nonDerivative · entry 5 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,420 F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $247.29 to $248.24. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 22:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 2,916 | $137.12 | $399,841.92 |
DisclosureSEC source: 0001737329-26-000016 · edgardoc.xml · nonDerivative · entry 4 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 22:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 27,584 | $137.12 | $3,782,318.08 |
DisclosureSEC source: 0001737329-26-000016 · edgardoc.xml · nonDerivative · entry 3 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 22:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 884 | $113.10 | $99,980.40 |
DisclosureSEC source: 0001737329-26-000016 · edgardoc.xml · nonDerivative · entry 2 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 22:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 26,116 | $113.10 | $2,953,719.60 |
DisclosureSEC source: 0001737329-26-000016 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 20:32 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001737329-26-000013 · wk-form4_1783974746.xml · derivative · entry 1 Iannone Robert · CIK 0001737329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-07-09 F1 · derivative.exercise_date: 1/36th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of July 9, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 22:16 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 3,764 | $237.72 | $894,778.08 |
DisclosureSEC source: 0001737329-26-000010 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,107 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:13 UTC | Autolus Therapeutics plc AUTL · Entity 1933 | GrantShare Option (Right to Buy) · Derivative | 47,500 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001730463-26-000099 · form4.xml · derivative · entry 2 Iannone Robert · CIK 0001737329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: American Depositary Shares · 47,500 shares Expires 2036-06-29 F3 · derivative.exercise_date: Share options vest in twelve equal monthly installments commencing on July 29, 2026. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:13 UTC | Autolus Therapeutics plc AUTL · Entity 1933 | GrantRestricted Share Units · Derivative | 31,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001730463-26-000099 · form4.xml · derivative · entry 1 Iannone Robert · CIK 0001737329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,667 Underlying: American Depositary Shares · 31,667 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share. F2 · derivative.exercise_date: The RSUs vest in one installment on June 29, 2027. F2 · derivative.expiration_date: The RSUs vest in one installment on June 29, 2027. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:21 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 6,209 | $188.69 | $1,171,576.21 |
DisclosureSEC source: 0001737329-26-000006 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,871 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:16 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 14,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001737329-26-000004 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,080 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| January 16, 2026 Filed Jan 22, 2026 00:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 4,140 | $171.16 | $708,602.40 |
DisclosureSEC source: 0001737329-26-000002 · edgardoc.xml · nonDerivative · entry 2 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,258 F3 · kind: Shares withheld from the vesting and distribution of performance share awards to satisfy the reporting person's tax obligations. Read SEC document |
| January 16, 2026 Filed Jan 22, 2026 00:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 11,699 | $0.00 | $0.00 |
DisclosureSEC source: 0001737329-26-000002 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,398 F1 · kind: Represents ordinary shares of the Issuer delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2023. The performance-based vesting requirements applicable to such awards were satisfied on January 16, 2026, which represents the date on which the level of performance attained was certified. F2 · balance_after: The Reporting Person acquired 71 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 28, 2025. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 01:31 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 7,159 | $168.26 | $1,204,573.34 |
DisclosureSEC source: 0001737329-25-000004 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,628 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 30, 2025. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 18:24 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 2,403 | $138.41 | $332,604.52 |
DisclosureSEC source: 0001765581-25-000035 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,621 Read SEC document |
| March 07, 2025 Filed Mar 7, 2025 23:49 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,548 | $140.00 | $216,720.00 |
DisclosureSEC source: 0001765581-25-000026 · edgardoc.xml · nonDerivative · entry 3 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,024 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 07, 2025 Filed Mar 7, 2025 23:49 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 5,532 | $138.21 | $764,577.72 |
DisclosureSEC source: 0001765581-25-000026 · edgardoc.xml · nonDerivative · entry 2 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,572 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $138.19 to $138.23. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 23:49 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Disposition to issuerOrdinary Shares | 5,239 | $138.95 | $727,959.05 |
DisclosureSEC source: 0001765581-25-000026 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D & CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,104 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 01:22 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 8,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-25-000020 · edgardoc.xml · nonDerivative · entry 2 Iannone Robert · CIK 0001737329 · EVP, G R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,343 F2 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units will vest in full on June 30, 2026. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 01:22 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 17,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-25-000020 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, G R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,484 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2025, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| January 17, 2025 Filed Jan 22, 2025 23:58 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 2,181 | $122.62 | $267,434.22 |
DisclosureSEC source: 0001805688-25-000013 · edgardoc.xml · nonDerivative · entry 2 Iannone Robert · CIK 0001737329 · EVP, G R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,766 F3 · kind: Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations. Read SEC document |
| January 17, 2025 Filed Jan 22, 2025 23:58 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 7,506 | $0.00 | $0.00 |
DisclosureSEC source: 0001805688-25-000013 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, G R&D and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,947 F1 · kind: Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2022. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2025, which represents the date on which the level of performance attained was certified. F2 · balance_after: The Reporting Person acquired 167 ordinary shares on May 31, 2024 and 48 ordinary shares on November 29, 2024 under a Section 423 Employee Stock Purchase Plan. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:00 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | GrantStock Option (Right to Buy) · Derivative | 24,200 | $0.00 Strike: $16.32 | $0.00 |
DisclosureSEC source: 0000950170-24-073251 · ownership.xml · derivative · entry 1 Iannone Robert · CIK 0001737329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,200 Underlying: Common Stock · 24,200 shares Expires 2034-06-11 Read SEC document |
| March 05, 2024 Filed Mar 8, 2024 02:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 4,294 | $117.53 | $504,673.82 |
DisclosureSEC source: 0001765581-24-000031 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,226 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 00:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 16,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-24-000017 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,520 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2024, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 23:25 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,730 | $119.13 | $206,094.90 |
DisclosureSEC source: 0001784606-24-000008 · edgardoc.xml · nonDerivative · entry 2 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,592 F3 · kind: Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 23:25 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 5,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001784606-24-000008 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,322 F1 · kind: Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on May 5, 2021. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2024, which represents the date on which the level of performance attained was certified. F2 · balance_after: The Reporting Person acquired 37 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 30, 2023. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 19:55 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | GrantStock Option (Right to Buy) · Derivative | 22,383 | $0.00 Strike: $14.77 | $0.00 |
DisclosureSEC source: 0001209191-23-037593 · doc4.xml · derivative · entry 1 Iannone Robert · CIK 0001737329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,383 Underlying: Common Stock · 22,383 shares Expires 2033-06-13 Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 23:16 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Disposition to issuerOrdinary Shares | 1,311 | $129.73 | $170,076.03 |
DisclosureSEC source: 0001765581-23-000048 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, Global Head of Research a 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,315 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: Includes 137 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2023. Read SEC document |
| May 03, 2023 Filed May 4, 2023 11:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $2.80 | Not disclosed |
DisclosureSEC source: 0001640455-23-000109 · wf-form4_168320062719961.xml · derivative · entry 4 Iannone Robert · CIK 0001737329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| May 03, 2023 Filed May 4, 2023 11:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,700 | Not disclosed Strike: $7.27 | Not disclosed |
DisclosureSEC source: 0001640455-23-000109 · wf-form4_168320062719961.xml · derivative · entry 3 Iannone Robert · CIK 0001737329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,700 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| May 03, 2023 Filed May 4, 2023 11:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,850 | Not disclosed Strike: $7.58 | Not disclosed |
DisclosureSEC source: 0001640455-23-000109 · wf-form4_168320062719961.xml · derivative · entry 2 Iannone Robert · CIK 0001737329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,850 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| May 03, 2023 Filed May 4, 2023 11:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 31,400 | Not disclosed Strike: $7.19 | Not disclosed |
DisclosureSEC source: 0001640455-23-000109 · wf-form4_168320062719961.xml · derivative · entry 1 Iannone Robert · CIK 0001737329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,400 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of March 26, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 3, 2023 (the "Effective Time"). F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| March 05, 2023 Filed Mar 8, 2023 02:22 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 2,274 | $142.78 | $324,681.72 |
DisclosureSEC source: 0001765581-23-000028 · edgardoc.xml · nonDerivative · entry 2 Iannone Robert · CIK 0001737329 · EVP, Global Head of Research a 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,489 F2 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 8, 2023 02:22 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 12,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-23-000028 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, Global Head of Research a 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,763 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 22:16 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,844 | $151.54 | $279,439.76 |
DisclosureSEC source: 0001765581-22-000138 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,316 F1 · balance_after: Includes 51 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2022. Read SEC document |
| June 24, 2022 Filed Jun 29, 2022 01:05 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001640455-22-000071 · wf-form4_165646470525225.xml · derivative · entry 1 Iannone Robert · CIK 0001737329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-24 F1 · derivative.exercise_date: The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2023 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 19:53 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | GrantStock Option (Right to Buy) · Derivative | 17,538 | $0.00 Strike: $18.78 | $0.00 |
DisclosureSEC source: 0001209191-22-036139 · doc4.xml · derivative · entry 1 Iannone Robert · CIK 0001737329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,538 Underlying: Common Stock · 17,538 shares Expires 2032-06-09 F1 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 9, 2023 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 21:01 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,295 | $149.25 | $193,278.75 |
DisclosureSEC source: 0001765581-22-000061 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,109 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: Includes 147 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2022. Read SEC document |
| March 05, 2022 Filed Mar 9, 2022 22:54 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,327 | $153.96 | $204,304.92 |
DisclosureSEC source: 0001765581-22-000019 · edgardoc.xml · nonDerivative · entry 2 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D and Ch 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,257 F3 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 03, 2022 Filed Mar 9, 2022 22:54 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 11,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-22-000019 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, Global Head of R&D and Ch 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,584 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2022, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. F2 · balance_after: Includes 124 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.